The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer.
| Autor: | Wasko JA; 1 Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA., Ustun C; 2 Department of Medicine, Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA., Birkenbach M; 3 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Faizer R; 4 Department of Surgery, Division of Vascular Surgery, University of Minnesota, Minneapolis, MN, USA., Green JS; 5 Department of Medicine, Division of Infectious Diseases, University of Minnesota, Minneapolis, MN, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2019 Apr; Vol. 25 (3), pp. 703-705. Date of Electronic Publication: 2017 Dec 29. |
| DOI: | 10.1177/1078155217748471 |
| Abstrakt: | Mycotic aneurysms are a fatal manifestation of disseminated fungal infections in immunocompromised hosts. We present a patient with an Aspergillus mycotic aneurysm after hematopoietic cell transplant. Due to CYP2C19 rapid metabolizer phenotype (*1/*17), therapeutic levels of voriconazole were unobtainable. Successful therapy was achieved with posaconazole salvage therapy and early, aggressive surgery. This case demonstrates the consequences of voriconazole rapid metabolism and the potential impact of genetic variants. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|